Rimeporide clinical study results in Duchenne presented
EspeRare presented its results of Rimeporide's phase Ib study in Duchenne muscular dystrophy patients at the 15th ICNMD conference in Vienna
About Rimeporide: An experimental treatment in clinical development for the treatment of a broad rang of patients with Duchenne muscular dystrophy (DMD). The EspeRare foundation has obtained the orphan drug status by the European Medicines Agency and the US Food and Drug Administration for Rimeporide in DMD.
About ICNMD: This international congress is organized on behalf of the Applied Research Group on Neuromuscular Diseases of the World Federation of Neurology. Since 2014, the Congress has taken place in two-year cycles. This was the 15th International Congress, the aim of the Congress is to present a wide spectrum of neuromuscular diseases from the perspectives of advances in research, diagnosis and treatment.